Literature DB >> 17699254

Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia.

Jula K Inrig1, Shelby D Reed, Lynda A Szczech, John J Engemann, Joelle Y Friedman, G Ralph Corey, Kevin A Schulman, L Barth Reller, Vance G Fowler.   

Abstract

The association between hemodialysis vascular access type, costs, and outcome of Staphylococcus aureus bacteremia (SAB) among patients with ESRD remains incompletely characterized. This study was undertaken to compare resource utilization, costs, and clinical outcomes among SAB-infected patients with ESRD by hemodialysis access type. Adjusted comparisons of costs and outcomes were based on multivariable linear regression and multivariable logistic regression models, respectively. A total of 143 hospitalized hemodialysis-dependent patients had SAB at Duke University Medical Center between July 1996 and August 2001. A total of 111 (77.6%) patients were hospitalized as a result of suspected bacteremia; 32 (22.4%) were hospitalized for other reasons. Of the 111 patients, 59.5% (n = 66) had catheters as their primary access type, 36% (n = 40) had arteriovenous (AV) grafts, and 4.5% (n = 5) had AV fistulas. Patients with fistulas were excluded from analyses because of small numbers. Patients with catheters were more likely to be white, had shorter dialysis vintage, and had higher Acute Physiology and Chronic Health Evaluation II scores compared with patients with grafts. Unadjusted 12-wk mortality did not significantly differ between patients with catheters compared with patients with grafts (22.7 versus 10.0%; P = 0.098); neither did 12-wk costs differ by access type ($22,944 +/- 18,278 versus $23,969 +/- 13,731, catheter versus graft; P > 0.05). In adjusted analyses, there was no difference in 12-wk mortality (odds ratio 1.63; 95% confidence interval 0.29 to 9.02; catheter versus graft) or 12-wk costs (means ratio 0.84; 95% confidence interval 0.60 to 1.17; catheter versus graft) among SAB-infected patients with ESRD on the basis of hemodialysis access type. Twelve-week mortality and costs that are associated with an episode of SAB are high in hemodialysis patients, regardless of vascular access type. Efforts should focus on the prevention of SAB in this high-risk group.

Entities:  

Mesh:

Year:  2006        PMID: 17699254     DOI: 10.2215/CJN.01301005

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  12 in total

1.  DNA microarray genotyping and virulence and antimicrobial resistance gene profiling of methicillin-resistant Staphylococcus aureus bloodstream isolates from renal patients.

Authors:  Sinead McNicholas; Anna C Shore; David C Coleman; Hilary Humphreys; Deirdre Fitzgerald Hughes
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

2.  Reducing catheter-related infections in hemodialysis patients.

Authors:  Daniel Landry; Gregory Braden
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237

Review 3.  Infectious complications in dialysis--epidemiology and outcomes.

Authors:  Philip Kam-Tao Li; Kai Ming Chow
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

4.  Catheter-related infections in chronic hemodialysis: a clinical and economic perspective.

Authors:  Gabriel Ştefan; Simona Stancu; Cristina Căpuşă; Oana Ramaiana Ailioaie; Gabriel Mircescu
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

5.  The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.

Authors:  Yeohan Song; Julie H Y Tai; Sarah M Bartsch; Richard K Zimmerman; Robert R Muder; Bruce Y Lee
Journal:  Vaccine       Date:  2012-03-29       Impact factor: 3.641

Review 6.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

7.  Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005-2011.

Authors:  Duc B Nguyen; Fernanda C Lessa; Ruth Belflower; Yi Mu; Matthew Wise; Joelle Nadle; Wendy M Bamberg; Susan Petit; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; Jamie Thompson; William Schaffner; Priti R Patel
Journal:  Clin Infect Dis       Date:  2013-08-19       Impact factor: 9.079

8.  Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.

Authors:  Yanhong Li; Joëlle Y Friedman; Betsy F O'Neal; Matthew J Hohenboken; Robert I Griffiths; Martin E Stryjewski; John P Middleton; Kevin A Schulman; Jula K Inrig; Vance G Fowler; Shelby D Reed
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 8.237

Review 9.  Catheter-related bloodstream infection in end-stage kidney disease: a Canadian narrative review.

Authors:  Chris Lata; Louis Girard; Michael Parkins; Matthew T James
Journal:  Can J Kidney Health Dis       Date:  2016-05-05

10.  Staphylococcus aureus Bacteremia Among Patients Receiving Maintenance Hemodialysis: Trends in Clinical Characteristics and Outcomes.

Authors:  Matthew R Sinclair; Maria Souli; Felicia Ruffin; Lawrence P Park; Michael Dagher; Emily M Eichenberger; Stacey A Maskarinec; Joshua T Thaden; Michael Mohnasky; Christina M Wyatt; Vance G Fowler
Journal:  Am J Kidney Dis       Date:  2021-07-23       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.